7 completed, 3 terminated, 1 active not recruiting. 2 Phase 1, 2 Phase 2, 2 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 4 | 1 | Terminated 1 |
Follow Theratechnologies: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA Ibalizumab - HIV-1-infection | Completed | Epividian | 141 | 2022-08-05 | 2023-09-07 | |
| The Visceral Adiposity Measurement and Observation Study Diagnostic Test, HIV Anti-retroviral Background Therapy - HIV, HIV-Infections | Completed | Theratechnologies | 196 | 2022-04-18 | 2023-11-18 | |
| A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab No ibalizumab or Pre-ibalizumab treatment, On ibalizumab treatment - HIV Infections, Multi-Antiviral Resistance | Completed | Theratechnologies | 168 | 2022-03-22 | 2026-07-27 | |
| TH1902 in Patients With Advanced Solid Tumors TH1902 - Solid Tumor, TNBC - Triple-Negative Breast Cancer | Phase 1 | Active not recruiting | Theratechnologies | 70 | 2021-03-04 | 2025-04-15 |
| Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Tesamorelin for injection - HIV | Terminated | Theratechnologies | 391 | 2013-02-01 | 2018-09-11 | |
| Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® Tesamorelin, Placebo-Control - Diabetic Retinopathy, HIV | Phase 4 | Terminated | Theratechnologies | 129 | 2012-06-01 | 2018-09-11 |
| Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting Tesamorelin, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Terminated | Theratechnologies | 3 | 2011-09-01 | 2022-03-18 |
| Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients Tesamorelin - HIV | Phase 1 | Completed | Theratechnologies | 18 | 2008-05-01 | 2013-12-16 |
| TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy Tesamorelin, Placebo for Tesamorelin - Lipodystrophy, HIV Infections | Phase 3 | Completed | Theratechnologies | 263 | 2007-08-01 | 2022-09-30 |
| TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 - HIV Infections, Lipodystrophy | Phase 3 | Completed | Theratechnologies | 412 | 2005-06-01 | 2013-11-27 |
| Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes TH9507 - Type 2 Diabetes | Phase 2 | Completed | Theratechnologies | 55 | 2002-02-01 | 2010-12-21 |
HIV Infections (4) · HIV-Associated Lipodystrophy Syndrome (2) · Lipodystrophy (2) · Acquired Immunodeficiency Syndrome (1) · Carcinoma, Ovarian Epithelial (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Retinopathy (1) · Endometrial Neoplasms (1) · Fatty Liver (1) · Liver Cirrhosis (1) · Liver Diseases (1) · Melanoma (1) · Muscular Atrophy (1) · Non-alcoholic Fatty Liver Disease (1) · Prostatic Neoplasms (1)
tesamorelin (7) · ibalizumab (2) · Diagnostic Tests, Routine (1) · Hematologic Tests (1) · Injections (1) · Tomography, X-Ray Computed (1) · Urination (1)
United States (8) · Canada (4) · Belgium (1) · France (1) · Spain (1) · United Kingdom (1)
Steven Grinspoon, MD (2) · Funda Meric-Burnstam, MD (1) · Jean-Claude Mamputu, PhD (1) · Jeffery Carr, DR (1) · John Koethe, MD (1) · Jordan Lake, MD (1) · Marilyn De Chantal (1) · Princy N Kumar, MD (1) · Richard Casaburi, PhD, MD (1) · Richard Larouche, MD (1)
PMID 20101189, PMID 20554713, PMID 22495074, PMID 28832410, PMID 18057338, PMID 28617838